Proton magnetic resonance spectroscopy in Huntington's disease: Evidence in favour of the glutamate excitotoxic theory?

Movement Disorders

Volumn 11, Issue 2, 1996, Pages 167-173

  Taylor Robinson, S D ^a   Weeks, R A ^a   Bryant, D J ^a   Sargentoni, J ^a   Marcus, C D ^a   Harding, A E ^b   Brooks, D J ^a,b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Excitotoxicity; Glutamate; Glutamine; Huntington's disease; Proton magnetic resonance spectroscopy

Indexed keywords

CHOLINE; CREATINE; GLUTAMIC ACID; GLUTAMINE; N ACETYLASPARTIC ACID;

ADULT; AMINO ACID METABOLISM; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; GENE LOCATION; HUMAN; HUNTINGTON CHOREA; MALE; NERVE DEGENERATION; OCCIPITAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TEMPORAL CORTEX; THALAMUS;

EID: 0029943742     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870110209     Document Type: Article

References (17)

1. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983.
2. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 1992;31:119-130.
3. Kreis R, Ross BD, Farrow NA, Ackerman Z. Metabolic disorders of the brain in chronic hepatic encephalopathy detected with H-1 MR spectroscopy. Radiology 1992;182:19-27.
4. Shoulson I. Huntington's disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology 1981;31:1333-1335.
5. Saeed N. A knowledge based approach to suppress water component in in vivo proton spectroscopy. Proceedings of the 12th Meeting of the Society of Magnetic Resonance Medicine 1993;1:403.
6. Frahm J, Bruhn H, Gyngell ML, Merboldt KD, Hanicke W, Sauter R. Localised proton NMR spectroscopy in different regions of the human brain in vivo. Relaxation and concentrations of cerebral metabolites. Magn Reson Med 1989;11: 47-63.
7. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994;330:613-622.
8. McBean GJ, Roberts PJ. Chronic infusion of L-glutamate causes neurotoxicity in the rat striatum. Brain Res 1984;290: 372-375.
9. Fonnum F, Storm-Mathisen J, Divac I. Biochemical evidence for glutamate as neurotransmitter in corticostriatal and corticothalamic fibres in rat brain. Neuroscience 1981; 6:863-874.
10. Isacson O, Fischer W, Wictorin K, Dawbarn D, Bjorkund A. Astroglial response in the excitotoxically lesioned neostriatum and its projection areas in the rat. Neuroscience 1987; 20:1043-1046.
11. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB. Replication of neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986;321: 168-171.
12. Schwarcz R, Whetsell WO, Mangano RM. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 1983;219:316-318.
13. Di Figlia M. Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci 1990;13:286-289.
14. Perry TL, Hansen S. What excitotoxin kills striatal neurons in Huntington's disease? Clues from neurochemical studies. Neurology 1990;40:20-24.
15. 1H NMR spectroscopy. Neurology 1993;43:2689-2695.
16. Bryant DJ, Sargentoni J, Cox IJ, et al. Proton magnetic resonance spectroscopy study of term infants with hypoxic ischaemic injury. Proceedings of the 2nd Meeting of the Society of Magnetic Resonance, San Francisco, 1994:336.
17. 1H-NMR spectroscopic studies of the brain. Neurosci Biobehav Rev 1989; 13:23-31.